Axovant Sciences (AXON) says Lunbeck study failure was expected - Bloomberg

September 22, 2016 3:40 PM EDT
Get Alerts AXON Hot Sheet
Trade AXON Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Axovant Sciences (NYSE: AXON) says Lunbeck study failure in Alzheimer's disease was expected, according to Bloomberg, citing a company email.

Axovant noted that weak efficacy in phase 3 wasn't surprising.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Trader Talk

Add Your Comment